# Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

> clinical trial · VERIFIED · 2026-07-13

Status: ACTIVE_NOT_RECRUITING · Sponsor: AstraZeneca · Condition: Hepatocellular Carcinoma

- Company: AstraZeneca
- Sector: Hepatocellular Carcinoma
- Primary source: https://clinicaltrials.gov/study/NCT05301842

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.